LONDON (Alliance News) - BTG PLC said Friday that the US Food and Drug Administration has approved Wellstat Therapeutics' Vistogard, a drug to treat patients following an overdose of chemotherapy drugs 5-fluorouracil or capecitabine.
Vistogard was approved following a priority review by the FDA. Following the approval BTG will market, sell and distribute the drug for this indication in the US.
"Severe 5-FU toxicity is an ongoing concern for the oncology community and, in some patients, it may go unrecognized. VISTOGARD not only saves lives but also helps some patients get back to fighting their cancer with chemotherapy. We're proud to add VISTOGARD to our portfolio of innovative products and potentially life-saving antidotes," said Chief Executive Officer Louise Makin in a statement.
Shares in BTG closed up 0.9% at 626.26 pence Friday.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
